Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 13/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9291226 | 0.88 | CYP2A6 (0.41) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL544426 | 0.78 | KDM4E (0.47) | ALDH1A1CYP1A2IDO1CHRM1ADORA2A | |
| SCHEMBL5932027 | 0.78 | CYP2A6 (0.50) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL7157794 | 0.78 | CYP2A6 (0.50) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL5931880 | 0.78 | CYP2A6 (0.53) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL6623741 | 0.76 | CHRM2 (0.57) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL9393916 | 0.76 | MAPT (0.42) | CYP3A4ALDH1A1CYP1A2CHRM1ADORA2A | |
| SCHEMBL7614581 | 0.74 | CHRM2 (0.69) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL7612811 | 0.74 | CYP2A6 (0.45) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 | |
| SCHEMBL29890067 | 0.73 | CYP2A6 (0.56) | CYP2A6CYP3A4ALDH1A1CYP1A2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026072607-A1 | PROCESS FOR PREPARING 3-CHLORO-4-(PYRIDIN-3-YL)-1,2,5-THIADIAZOLE | Karuna Therapeutics, Inc. (US) | 2026-04-02 | — | — | WO | disclosed |
| WO-2026072607-A1 | PROCESS FOR PREPARING 3-CHLORO-4-(PYRIDIN-3-YL)-1,2,5-THIADIAZOLE | Karuna Therapeutics, Inc. (US) | 2026-04-02 | — | — | WO | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-120965678-A | Preparation method of penomelin intermediate | 上海法默生物科技有限公司 | 2025-11-18 | — | — | CN | disclosed |
| CN-120794970-A | Preparation method of intermediate of penomelin | 奥锐特药业股份有限公司 | 2025-10-17 | — | — | CN | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-115974863-B | Malate and A crystal forms of taking-up nonimeilin derivative, preparation method and application thereof | 南京迈诺威医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-5328924-A | Thiadiazole hydropyridines as cognition activators for Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1994-07-12 | — | — | US | disclosed |
| US-5284859-A | Analgesics, Alzheimer's disease | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| US-5264444-A | Cognition activators | NOVO NORDISK A/S (DK) | 1993-11-23 | — | — | US | disclosed |
| US-5260311-A | Cognition activators, analgesics for sever pain, glaucoma treatment | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| EP-0544756-A1 | 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003430-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | disclosed |
| US-5043345-A | Cognition activators; alzheimer's disease | NOVO NORDISK A/S (DK) | 1991-08-27 | — | — | US | disclosed |
| US-5041455-A | Stimulants of cognitive function in mammals | NOVO NORDISK A/S (DK) | 1991-08-20 | — | — | US | disclosed |
| CN-1045104-A | Piperidine compounds and preparation thereof and purposes | FERROSAN AS (DK) | 1990-09-05 | — | — | CN | disclosed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | CYP2A6 693/4885CYP3A4 665/4885ALDH1A1 1582/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | CYP2A6 693/4885CYP3A4 665/4885ALDH1A1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.